Skip to main content
. 2012 Feb;3(Suppl 1):59–66. doi: 10.1055/s-0031-1298610

Table 1. Inclusion and exclusion criteria and demographics for the two included FDA trials providing long-term follow-up data.*.

Inclusion Exclusion
Burkus et al 1 (2010)
Prestige C-ADR
N = 541
Male: 46%
Mean age: 43.6 (22–73) y
C-ADR: n = 276
Male: 46.4%
Mean age: 43.3 (25–72) y
Fusion: n = 265
Male: 46.0%
Mean age: 43.9 (22–73) y
  • Adults >18 years of age

  • Single-level symptomatic DDD between C3-7

  • Intractable radiculopathy, myelopathy or both

  • NDI scores ≥ 30

  • VAS neck pain scores ≥ 20

  • Preserved motion at the symptomatic level found in all included patients

  • Unresponsive to ≥ 6 weeks conservative treatment or progressive neurological worsening despite conservative treatment

  • No previous procedures at the operative level

  • Negative for several radiographic findings, medications, and diagnoses

  • Multilevel symptomatic DDD or evidence of cervical instability

  • Sagittal plane translation of > 3.5 mm or sagittal plane angulation of >20° at a single level

  • Symptomatic C2-C3 or C7-T1 disc disease

  • Previous surgery at the involved level

  • Severe facet joint disease at the involved level

  • History of discitis

  • Osteoporosis

  • Metastases

  • Medical condition that required long-term use of medication, such as steroid or nonsteroidal antiinflammatory drugs that could affect bone quality and fusion rates

Sasso et al 2 (2011)
Bryan C-ADR
N = 463
Male: 48%
Mean age: 44.5 (25–78) y
C-ADR: n = 242
Male: 45.5%
Mean age: 44.4 (25–78) y
Fusion: n = 221
Male: 51.1%
Mean age: 44.7 (27–68) y
  • DDD at single level between C3 and C7

  • Disc herniation with radiculopathy, spondylotic radiculopathy, disc herniation with myelopathy, or spondylotic myelopathy

  • 6 weeks minimum unsuccessful conservative unless myelopathy requiring immediate treatment

  • CT, myelography and CT, and/or MRI demonstration of need for surgical treatment

  • ≥21 years old

  • Preoperative NDI ≥ 30 and minimum one clinical sign associated with level to be treated

  • Willing to sign informed consent and comply with protocol

  • Significant cervical anatomical deformity

  • Moderate to advanced spondylosis

  • Any combination of bridging osteophytes, marked reduction, or absence of motion

  • Collapse of intervertebral disc space of > 50% normal height, radiographic signs of subluxation > 3.5 mm, angulation of disc space > 11° greater than adjacent segments, significant kyphotic deformity or reversal or lordosis

  • Axial neck pain as solitary symptom

  • Previous cervical spine surgery

  • Metabolic bone disease

  • Active systemic infection or infection at operative site

  • Known allergy to components of titanium, polyurethane, ethylene oxide residuals

  • Concomitant conditions requiring steroid treatment

  • Daily insulin management

  • Extreme obesity

  • Medical condition which may interfere with postoperative management program or may result in death before study completion

  • Pregnancy

  • Current or recent alcohol and/or drug abuser

  • Signs of being geographically unstable

*

FDA indicates US Food and Drug Administration; DDD, degenerative disc disease; NDI, Neck Disability Index; VAS, Visual Analog Scale; CT, computed tomography; and MRI, magnetic resonance scan.